This is the same message we have heard time and time again, only modified a bit. Unfortunately, nothing ever materializes.
From September 2018:
“The Company’s pipeline is as mature as it has ever been,” noted Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals. “We have made substantial clinical progress with what we have accomplished to date, and remain committed to translating this into shareholder value. With partnering discussions ongoing, as well as active efforts underway to secure additional sources of capital, the prospects of our loyal shareholders are of paramount concern and front-of-mind as we strive to execute on these opportunities. We will continue to work tirelessly on their behalf as we advance the development of our clinical drug candidates.”
From October 2017:
“On the heels of a successful Proof-of-Concept study of Brilacidin in IBD, we look forward to continuing the Company’s momentum in this area,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Given IBD’s complex pathogenesis and variability in patient response to any one drug, new treatments are needed. More broadly, discussions remain ongoing with numerous global pharmaceutical companies, which, like us, see the considerable potential of Brilacidin as a multi-faceted drug candidate, with possible application across multiple therapeutic areas.
From December 2016:
"Looking ahead to 2017, we intend to remain laser focused on advancing our clinical pipeline with concurrent nurturing of relationships that can potentially lead to partnerships. Productive initial dialogue with major pharmaceutical companies in 2016 has already provided clear directions."
From December 2013:
"Leo Ehrlich, Chief Executive Officer, of Cellceutix commented, “Since last month’s Elsevier conference, we have entered into two confidentiality agreements with multi-billion dollar companies interested in our pipeline. We have a lot to accomplish over the coming weeks, which should set Cellceutix up for an exciting new year. We will provide shareholders with a more comprehensive update during the JP Morgan conference in January 2014.”
From June 2011:
"Kevetrin™ has now attracted the attention of many in the pharmaceutical industry with calls and emails coming in regularly to Cellceutix for additional technical information.
“When dealing with the most prestigious institutions globally, the wheels turn a bit slow due to the thorough due diligence of those organizations. These things are unfortunately out of our hands. Most companies never even get this kind of opportunity and it is a vote of confidence in Kevetrin™,” commented Cellceutix CEO Leo Ehrlich. “We are being extremely well thought-out in making decisions as we are in a very unique position with Kevetrin™. We are evaluating every possible scenario that will maximize shareholder value. The word of Kevetrin™ is spreading throughout the industry as is evident in the fact that we have been contacted by many of the world’s foremost pharmaceutical companies inquiring about Kevetrin™. We are as optimistic as ever about our valuable compound and while we aren’t at liberty to discuss all of the details, things are progressing in an extremely positive manner.”
Market Data 
Markets 
AI
